Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae

A. Lombardi, L. Drago, E. De Vecchi, B. Mombelli, M. R. Gismondo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Chlamydia pneumoniae is responsible for respiratory tract infections of both upper and lower respiratory tract. Although this bacterium is one of the most widespread pathogens of man, there are limited data on the antibiotic treatment of C. pneumoniae infections. The aim of this study has been to evaluate the in vitro activity of thiamphenicol glycinate acetylcysteinate (TGA, CAS 20192-91-0) in comparison with molecules with established activity against C. pneumoniae, as well as macrolides and quinolones. The results have shown that TGA and clarithromycin (CAS 81103-11-9) are the most active drugs tested, but it is important to underline that the minimal inhibitory concentration (MIC) ranges of TGA are very much lower than the breakpoint of thiamphenicol for the respiratory pathogens. In conclusion, the good antimicrobial in vitro activity of TGA against C. pneumoniae together with its in vivo characteristics, in particular the high concentration reached in lung and the combination with the mucolytic agent N-acetylcysteine (NAC, CAS 616-91-1), can make a valid choice in the treatment of respiratory tract infections caused by C. pneumoniae. These findings need further evaluation by clinical studies.

Original languageEnglish
Pages (from-to)264-267
Number of pages4
JournalArzneimittel-Forschung/Drug Research
Volume51
Issue number3
Publication statusPublished - 2001

Fingerprint

Chlamydophila pneumoniae
Pathogens
Thiamphenicol
Expectorants
Clarithromycin
Quinolones
Macrolides
Acetylcysteine
Pharmaceutical Preparations
Bacteria
Respiratory Tract Infections
Anti-Bacterial Agents
Molecules
Chlamydia Infections
Respiratory System
thiamphenicol glycinate acetylcysteinate
Lung
Therapeutics

Keywords

  • Antimicrobial susceptibility
  • CAS 81103-11-9
  • Chlamydia pneumoniae
  • Chloramphenicol
  • Respiratory tract infections
  • Thiamphenicol glycinate acetylcysteinate

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae. / Lombardi, A.; Drago, L.; De Vecchi, E.; Mombelli, B.; Gismondo, M. R.

In: Arzneimittel-Forschung/Drug Research, Vol. 51, No. 3, 2001, p. 264-267.

Research output: Contribution to journalArticle

@article{f03c1852e17c46f0907b370bc3496c91,
title = "Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae",
abstract = "Chlamydia pneumoniae is responsible for respiratory tract infections of both upper and lower respiratory tract. Although this bacterium is one of the most widespread pathogens of man, there are limited data on the antibiotic treatment of C. pneumoniae infections. The aim of this study has been to evaluate the in vitro activity of thiamphenicol glycinate acetylcysteinate (TGA, CAS 20192-91-0) in comparison with molecules with established activity against C. pneumoniae, as well as macrolides and quinolones. The results have shown that TGA and clarithromycin (CAS 81103-11-9) are the most active drugs tested, but it is important to underline that the minimal inhibitory concentration (MIC) ranges of TGA are very much lower than the breakpoint of thiamphenicol for the respiratory pathogens. In conclusion, the good antimicrobial in vitro activity of TGA against C. pneumoniae together with its in vivo characteristics, in particular the high concentration reached in lung and the combination with the mucolytic agent N-acetylcysteine (NAC, CAS 616-91-1), can make a valid choice in the treatment of respiratory tract infections caused by C. pneumoniae. These findings need further evaluation by clinical studies.",
keywords = "Antimicrobial susceptibility, CAS 81103-11-9, Chlamydia pneumoniae, Chloramphenicol, Respiratory tract infections, Thiamphenicol glycinate acetylcysteinate",
author = "A. Lombardi and L. Drago and {De Vecchi}, E. and B. Mombelli and Gismondo, {M. R.}",
year = "2001",
language = "English",
volume = "51",
pages = "264--267",
journal = "Arzneimittel-Forschung/Drug Research",
issn = "0004-4172",
publisher = "Editio Cantor Verlag GmbH",
number = "3",

}

TY - JOUR

T1 - Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae

AU - Lombardi, A.

AU - Drago, L.

AU - De Vecchi, E.

AU - Mombelli, B.

AU - Gismondo, M. R.

PY - 2001

Y1 - 2001

N2 - Chlamydia pneumoniae is responsible for respiratory tract infections of both upper and lower respiratory tract. Although this bacterium is one of the most widespread pathogens of man, there are limited data on the antibiotic treatment of C. pneumoniae infections. The aim of this study has been to evaluate the in vitro activity of thiamphenicol glycinate acetylcysteinate (TGA, CAS 20192-91-0) in comparison with molecules with established activity against C. pneumoniae, as well as macrolides and quinolones. The results have shown that TGA and clarithromycin (CAS 81103-11-9) are the most active drugs tested, but it is important to underline that the minimal inhibitory concentration (MIC) ranges of TGA are very much lower than the breakpoint of thiamphenicol for the respiratory pathogens. In conclusion, the good antimicrobial in vitro activity of TGA against C. pneumoniae together with its in vivo characteristics, in particular the high concentration reached in lung and the combination with the mucolytic agent N-acetylcysteine (NAC, CAS 616-91-1), can make a valid choice in the treatment of respiratory tract infections caused by C. pneumoniae. These findings need further evaluation by clinical studies.

AB - Chlamydia pneumoniae is responsible for respiratory tract infections of both upper and lower respiratory tract. Although this bacterium is one of the most widespread pathogens of man, there are limited data on the antibiotic treatment of C. pneumoniae infections. The aim of this study has been to evaluate the in vitro activity of thiamphenicol glycinate acetylcysteinate (TGA, CAS 20192-91-0) in comparison with molecules with established activity against C. pneumoniae, as well as macrolides and quinolones. The results have shown that TGA and clarithromycin (CAS 81103-11-9) are the most active drugs tested, but it is important to underline that the minimal inhibitory concentration (MIC) ranges of TGA are very much lower than the breakpoint of thiamphenicol for the respiratory pathogens. In conclusion, the good antimicrobial in vitro activity of TGA against C. pneumoniae together with its in vivo characteristics, in particular the high concentration reached in lung and the combination with the mucolytic agent N-acetylcysteine (NAC, CAS 616-91-1), can make a valid choice in the treatment of respiratory tract infections caused by C. pneumoniae. These findings need further evaluation by clinical studies.

KW - Antimicrobial susceptibility

KW - CAS 81103-11-9

KW - Chlamydia pneumoniae

KW - Chloramphenicol

KW - Respiratory tract infections

KW - Thiamphenicol glycinate acetylcysteinate

UR - http://www.scopus.com/inward/record.url?scp=0035080094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035080094&partnerID=8YFLogxK

M3 - Article

C2 - 11304944

AN - SCOPUS:0035080094

VL - 51

SP - 264

EP - 267

JO - Arzneimittel-Forschung/Drug Research

JF - Arzneimittel-Forschung/Drug Research

SN - 0004-4172

IS - 3

ER -